Project Details
Description
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study
| Status | Active |
|---|---|
| Effective start/end date | 6/1/21 → 5/31/26 |
Funding
- INCYTE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.